Making Genomics Work for Pharma

 
 
By Stacy Lawrence  |  Posted 2004-07-07 Email Print this article Print
 
 
 
 
 
 
 

A series of executive interviews examines how pharmaceutical companies are making use of the massive technological advances of the last five years in genomics.

With the explosion of data-intensive research tools, pharmaceutical companies are still struggling to understand how to most effectively make use of them. This package has the first few of a series of interviews with pharmaceutical executives about how are beginning to use genomics to enhance their drug discovery pipelines. It examines the usefulness of microarrays, proteomics, genotyping, RNAi and other genomic tools. It includes interviews from top executives with Pfizer, GlaxoSmithKline, Astrazeneca, and Merck.

Read the full story at Bio-IT World


 
 
 
 
Stacy Lawrence is co-editor of CIOInsight.com's Health Care Center. Lawrence has covered IT and the life sciences for various publications, including Business 2.0, Red Herring, The Industry Standard and Nature Biotechnology. Before becoming a journalist, Lawrence attended New York University and continued on in the sociology doctoral program at UC Berkeley.
 
 
 
 
 
 
 

Submit a Comment

Loading Comments...

 
Manage your Newsletters: Login   Register My Newsletters























 
 
 
 
 
 
 
 
 
 
 
Rocket Fuel